Firehawk Rapamycin Target Eluting Coronary Stent North American Trial

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 1720 participants.

Also called NCT04562532

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 1,720 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04562532
Other papers using this trial's data
  • Randomized Comparison of Novel Low-Dose Sirolimus-Eluting Biodegradable Polymer Stent vs Second-Generation DES: TARGET-IV NA Trial Journal of the American College of Cardiology, 2025-02-18 DOI, PubMed 39480379

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Belgium, Canada, Denmark, Netherlands (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT04562532. Randomized; no masking; primary purpose treatment. Start 2021-02-17 (actual); primary completion 2023-12-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Firehawk Rapamycin Target Eluting Coronary Stent North American Trial
Acronym
TARGET-IV_NA
Intervention (Device)
Microport Firehawk stent
Intervention (Device)
2nd generation DES (XIENCE family, Promus family, Resolute/Onyx family/Endeavor, and Orsiro stent)
Lead sponsor
Shanghai MicroPort Medical (Group) Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct04562532
Content hash
f0e279b3be54c6f19120926e7a8a1c8ff06da0888b776d4aa6fd1d7609bcfdb4